← All trials
NCT06801236
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2025
- Primary completion
- Mar 1, 2028
- Completion date
- Aug 1, 2028
- First posted
- Jan 30, 2025
- Last posted
- Jul 28, 2025
- Enrollment
- 67
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Acerand Therapeutics (Hong Kong) LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.